Rekvina Laboratories Ltd - 526075 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Rekvina Laboratories shareholders have approved all proposed resolutions at the Extra-Ordinary General Meeting held on April 10, 2026. Key approvals include an increase in authorized share capital and two preferential issues of equity shares, enhancing the company's financial flexibility and capital structure.
Apr 10 2026 17:04:00
Rekvina Laboratories Ltd - 526075 - Announcement under Regulation 30 (LODR)-Open Offer - Updates
Acquirers for Rekvina Laboratories Limited announced an open offer to acquire up to 26% of its expanded share capital at ₹10 per share, aggregating ₹2.89 crore. The offer's tendering period is from May 14 to May 27, 2026, and is triggered by Rekvina's prior acquisition of Radiant Parenterals Limited via a share swap.
Apr 02 2026 18:04:00
Rekvina Laboratories Ltd - 526075 - Announcement under Regulation 30 (LODR)-Open Offer - Updates
Rekvina Laboratories' promoters launched an open offer to acquire up to 26% stake at ₹10 per share. This move aims to consolidate promoter shareholding, which is projected to reach 90.03% post-offer, following the acquisition of Radiant Parenterals Limited.
Mar 24 2026 18:03:00
Rekvina Laboratories Ltd - 526075 - Detailed Public Statement
Rekvina Laboratories announced a mandatory open offer to acquire 26% of its expanded share capital at ₹10 per share. The offer, valued at ₹2.89 crore, is a direct consequence of its acquisition of Radiant Parenterals Limited via a share swap agreement.
Mar 24 2026 14:03:00
Read More